Baicalin promotes the viability of Schwann cells in vitro by regulating neurotrophic factors
Authors: Peizhen Lv
Li Zheng
Fuben Xu
Wenpu Zuo
Kun Zhang
Huayu Wu
Weizhe Jiang
Jinmin Zhao
Journal: Experimental and Therapeutic Medicine (2017)
Discipline: CLINICAL MEDICINE
Keywords: RSC96; Schwann cell; baicalin; brain-derived neurotrophic factor; ciliary neurotrophic factor
Affiliations: Medical and Scientific Research Center, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China., Department of Cell Biology and Genetics, School of Premedical Sciences, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China., Guangxi Key Laboratory of Regenerative Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China., Department of Orthopedic Trauma and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China., Key Laboratory of Regenerative Medicine of Guangxi High School, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China., Department of Pharmacology, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China.

Abstract:  The proliferation and migration of Schwann cells (SCs) are key events in the process of peripheral nerve repair. This is required to promote the growth of SCs and is a challenge during the treatment of peripheral nerve injury. Baicalin is a natural herb-derived flavonoid compound, which has been reported to possess neuroprotective effects on rats with permanent brain ischemia and neuronal differentiation of neural stem cells. The association of baicalin with neuroprotection leads to the suggestion that baicalin may exert effects on the growth of SCs. In the present study, the effects of baicalin on SCs of RSC96 were investigated. RSC96 SCs were treated with various concentrations of baicalin (0, 5, 10 or 20 µM) for 2, 4 and 6 days. Cell attachment, viability and gene expression were monitored via the MTT assay and reverse transcription-quantitative polymerase chain reaction. The gene expression levels of several neurotrophic factors, such as glial cell-derived neurotrophic factor, brain-derived neurotrophic factor and ciliary neurotrophic factor, which are considered important factors in the process of never cell regeneration, were detected. The results indicated that baicalin was able to promote the viability of RSC96 SCs in a dose-dependent manner and the concentration of 20 µM of baicalin exhibited the greatest cell viability and gene expression of the studied neurotrophic factors. The present findings suggested that baicalin likely affects SCs metabolism, through modulating the expression of neurotrophic factors. To conclude, the present study indicates that baicalin may be potential therapeutic agent for treating peripheral nerve regeneration. 

Retracted: No

PubPeer comments:
 Figure 5: Microscopy data has been duplicated and prestented as something else (4 days; control vs 5 u00b5M Baikalin). ![file] , 
 Corrigendum, [13 December 2021] . ------------------------------ After the publication of the above article, the authors have realized that Figs. 3, 5 and 7 in their paper were published with errors; regarding Fig. 3, the data panel for the u20182 days, 5 u00b5M baicalinu2019 experiment was selected incorrectly, whereas with Figs. 5 and 7, an incorrect data panel was selected for the u2018Control, 4 daysu2019 data. These errors arose inadvertently as a consequence of the authorsu2019 misfiling of their data. The revised versions of Figs. 3, 5 and 7, featuring the corrected data panels for the aboveu2011mentioned experiments, are shown opposite. Note that the revised data shown for these Figures do not affect the overall conclusions reported in the paper. The authors apologize to the Editor of *Experimental and Therapeutic Medicine* and to the readership for any inconvenience caused. ![file] ,